Increased Use of DPP-4, SGLT-2 Inhibitors for Diabetic Nephropathy
DPP-4 inhibitors use was used in 54% of treatment visits by the last quarter of 2014; ACEIs and ARBs were prescribed in the majority of treatment visits with peaks above 90%.
(HealthDay News) — From 2010 to 2014 there was an increase in use of diabetes medications, including sulfonylureas and dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), among patients with diabetic nephropathy, according to a study published online in the Journal of Clinical Pharmacy and Therapeutics.
Using the IMS Health's National Disease and Therapeutic Index, Oyintayo Ajiboye, MD, MPH, and Jodi B. Segal, MD, MPH, from the Johns Hopkins Bloomberg School of Public Health in Baltimore, analyzed medication prescription patterns for 6 classes of medications among patients with diabetic nephropathy.
The researchers observed an increase in the number of annual office visits, from 772,860 in 2010 to 1,868,618 in 2013, followed by a decrease to 830,596 in 2014. Of the 4 classes of diabetes medications included in the study, the most frequently used were sulfonylureas and DPP-4 inhibitors. Use of DDP-4 inhibitors gradually increased; by the last quarter of 2014 they were used in 54% of treatment visits. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were prescribed in most treatment visits across these years, with peaks above 90%, although there were some periods when their use was low.
"Future studies should assess if the utilization of these medications continues to increase over time and should generate more evidence on the factors affecting the different treatment options so that more focused interventions can be done to improve patient outcomes," the authors write.
- Ajiboye O, Segal JB. National trends in the treatment of diabetic nephropathy in the United States. J Clin Pharm Ther. 15 March 2017. doi: 10.1111/jcpt.12516